Journal
JOURNAL OF MEDICINAL FOOD
Volume 24, Issue 1, Pages 1-9Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jmf.2020.4750
Keywords
allergic rhinitis; Astragalus polysaccharides; Caspase-1; NF-kappa B; NLRP3 inflammasome; Nod2
Funding
- Natural Science Foundation of Guangdong Province [2017A030313626]
- Social Public Welfare and Basic Research Project of Zhongshan Science and Technology Bureau [2020B1096]
- Excellent Young Scholars Project of the First Affiliated Hospital of Guangzhou University of Chinese Medicine [2019QN22, 2017ZWB10]
Ask authors/readers for more resources
Astragalus polysaccharides (APS) have anti-inflammatory effects on ovalbumin-induced allergic rhinitis in rats by alleviating nasal symptoms, reducing inflammatory cytokine levels, inhibiting NLRP3 inflammasome activation, and blocking NF-kappa B activation. These findings suggest that APS may serve as a potential therapeutic agent for allergic rhinitis.
Allergic rhinitis (AR) is an IgE-mediated chronic inflammatory disease of the allergic nasal mucosa. It has a significant effect on quality life; most patients with AR also suffer from sleep disorders, mood disorders, and deterioration in social relationships. As increasing numbers of medicinal plants show productive anti-inflammatory activity against inflammatory diseases, there is growing interest in natural medicinal plant ingredients. To this end, we selected Astragalus polysaccharides (APS) to evaluate its anti-inflammatory effect on ovalbumin-induced AR rats, and we further explored its impact on NLRP3 inflammasome activation and NOD2-mediated NF-kappa B activation. We found that APS can alleviate the nasal symptom of AR rats and attenuate pathological alterations. APS also reduced the inflammatory cytokine levels. APS not only inhibited the NLRP3 inflammasome activation but also inhibited NF-kappa B activation by decreasing NOD2 expression and blocking the phosphorylation of NF-kappa B (p65). In conclusion, APS can effectively improve the inflammatory symptoms of nasal mucosa in AR rats, which may be mediated by the inhibition of NLRP3 inflammasome activation and NOD2-mediated NF-kappa B activation. These findings indicate that APS has the potential to be used as a therapeutic agent for AR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available